Answers are grounded in this paper and cite their sources.
Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory requirements for registration apply. Whereas pharmaceutical quality evaluation requires a full dossier and a detailed comparative analysis to the reference drug, non-clinical and clinical requirements are much less extensive compared to the requirements for an innovator. Limited clinical experience and their complex nature exclude biosimilars from being considered interchangeable with the reference drug.
No takes yet. Share an insight, caveat, or question.
Paul Declerck (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: